Published: July 12, 2026 | Category: Markets / Venture Capital & Private Equity
Jeff Bezos is opening Blue Origin’s doors to outside money for the first time, and the price of admission values his rocket company at $130 billion — a fraction of what his chief rival just fetched on the public market, but a staggering figure for a company that has yet to prove its flagship vehicle can fly reliably.
Blue Origin is finalizing a $10 billion raise led by Coatue Management, according to people familiar with the deal, in what would be the company’s first external fundraising round since Bezos founded it in 2000. Coatue is expected to commit roughly $4 billion, with Bezos himself putting in another $2 billion and a syndicate of other large investors filling out the rest. The round arrives weeks after New Glenn, Blue Origin’s flagship heavy-lift rocket, exploded during ground testing in late May while being prepared for its fourth launch — and just a month after Elon Musk’s SpaceX closed a roughly $86 billion initial public offering, the largest in history, that implicitly set the bar Blue Origin is now being measured against and found short of by a wide margin.
The Blue Origin round was the marquee item in what amounted to one of the busiest weeks of the year for private capital deployment. AI chipmaker SambaNova closed part of a planned $1 billion Series F at an $11 billion post-money valuation, led by General Atlantic with participation from BlackRock and Qatar Investment Authority — a sign that late-stage AI infrastructure investing has not cooled despite two years of warnings about a bubble. Smaller but still substantial rounds went to EDX Markets ($76 million Series C, led by SBI Holdings), Pearl Health ($50 million Series C plus a $60 million credit facility, led by a16z), and roughly a dozen seed and Series A deals spread across defense technology, ad-tech, fintech and healthtech.
Private equity was equally active, though in a lower register. KKR-backed Barracuda Networks acquired identity-security firm Evo Security; EQT agreed to buy Corza Biosurgery from GTCR’s Corza Medical; and Frazier Healthcare Partners struck a deal to acquire electronic health-records provider MatrixCare from ResMed for $490 million — part of a broader pattern of mid-market buyout shops picking off healthcare-services assets that larger strategics no longer want to carry.
Public markets and strategic M&A rounded out the picture. Chinese connector maker Luxshare raised $3.1 billion in a Hong Kong listing. Dream Finders Homes raised its bid for rival homebuilder Beazer Homes to roughly $875 million. Infrastructure-services firm MasTec agreed to buy Superior Group for $1.65 billion in cash and stock, and Ecolab closed its previously announced $4.75 billion purchase of data-center cooling specialist CoolIT Systems from KKR. On the fundraising side, San Francisco venture firm Chemistry began raising up to $500 million for its second fund, while SkyKnight Capital closed $2 billion for its fifth.
This Week’s Deal Flow at a Glance
| Company / Target | Deal Type | Amount | Lead Investor(s) / Acquirer |
|---|---|---|---|
| Blue Origin | First outside funding round | $10B at $130B valuation | Coatue Management |
| SambaNova | Series F (partial close) | $1B at $11B post-money | General Atlantic |
| EDX Markets | Series C | $76 million | SBI Holdings |
| Pearl Health | Series C + credit facility | $50M + $60M | a16z |
| Evo Security | Acquisition | Undisclosed | Barracuda Networks (KKR-backed) |
| Corza Biosurgery | Acquisition | Undisclosed | EQT (from GTCR’s Corza Medical) |
| MatrixCare | Acquisition | $490 million | Frazier Healthcare Partners (from ResMed) |
| Luxshare | Hong Kong IPO | $3.1 billion | — |
| Beazer Homes | Raised takeover bid | ~$875 million | Dream Finders Homes |
| Superior Group | Acquisition | $1.65 billion | MasTec |
| CoolIT Systems | Acquisition (closed) | $4.75 billion | Ecolab (from KKR) |
| Chemistry Fund II | VC fundraising | Up to $500 million | — |
| SkyKnight Capital Fund V | PE fund close | $2 billion | — |
Taken together, the week’s flow of capital tells a bifurcated story. At the frontier — rockets, AI chips — investors are still willing to underwrite enormous valuations against unproven execution, betting that scale and access matter more than near-term profitability. Further down the market, private equity is running a quieter, more disciplined playbook: buying healthcare, industrial-services and infrastructure assets at steady multiples, betting on consolidation rather than moonshots. Both bets are being placed with the same pool of capital, in the same week, a reminder that the current market has room for both New Glenn’s ambitions and MatrixCare’s balance sheet.
Bloom Capital Review 
Leave a comment